SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation

Recruiting now · Not applicable

Conditions studied: Atrial Fibrillation

In brief

This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to \<30%).

Key facts

Study ID

NCT05794386

Run by

Seoul National University Hospital

People needed

204

Starts

2023-02-01

Expected to finish

2027-12-31

Last updated by the study team

2026-04-28

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or
• Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1)
• Patients with an LVA of <1cm2 or ≥30% are recruited as a registry.

You may not qualify if…

• Patients with LA anteroposterior diameter of more than 55 mm
• Patients with prior AF-related catheter ablation or surgery
• Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure.
• Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation)
• Known severe left ventricular systolic dysfunction (ejection fraction <35%)
• Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases)
• Patients with intracardiac thrombus
• Patients with prior cardiac surgery
• Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months
• Patients who had a stroke or transient ischemic attack within 6 months
• Patients who had a planned operation or procedure for the cardiovascular system
• Patients with intractable hypertension or uncontrolled thyroid disease
• Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis
• Patients who are currently pregnant or are likely to be pregnant within the study period
• Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc
• Patients whose life expectancy is less than 1 year

Where it is running

• Seoul National University Hospital — Seoul, Jongno-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.